REGULATED INFORMATION
GHENT, Belgium,
28 May 2018 - Ablynx [Euronext Brussels and
Nasdaq: ABLX] today announced, in accordance with Article 14 of
the Belgian Law of 2 May 2007 regarding the publication of major
shareholdings in issuers whose securities are admitted to trading
on a regulated market (the "Transparency Law"), that it received
notifications of shareholdings from Farallon Capital Management,
LLC; Marshall Wace LLP; Van Herk Investments B.V.; and Davidson
Kempner Capital Management LLP.
These major shareholders (taking
into account the holdings of their subsidiary undertakings)
notified Ablynx that they have downward crossed the lowest
threshold (3%) of total voting rights of Ablynx.
More information is available in
the transparency notifications. Full versions of the transparency
notification are available on Ablynx website, under the section
Investors.
The Articles of the Association of
Ablynx NV provide for shareholders notification threshold of 3%, 5%
or a multiple of 5% of the total number of existing voting
rights.
About
Ablynx
Ablynx is a biopharmaceutical
company engaged in the development of Nanobodies, proprietary
therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with
some of the features of small-molecule drugs. Ablynx is dedicated
to creating new medicines which will make a real difference to
society. Today, the Company has more than 45 proprietary and
partnered programmes in development in various therapeutic areas
including inflammation, haematology, immuno-oncology, oncology and
respiratory disease. The Company has collaborations with multiple
pharmaceutical companies including AbbVie; Boehringer Ingelheim;
Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA;
Merck KGaA; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The
Company is headquartered in Ghent, Belgium. More information can be
found on www.ablynx.com.
On 29 January 2018, Sanofi made an
offer to acquire all of Ablynx's outstanding ordinary shares
(including shares represented by American Depository Shares (ADSs),
warrants and convertible bonds (collectively with the outstanding
ordinary shares, the "Securities")) at a price
of €45 per share, which represents an aggregate equity value of
approximately €3.9 billion. The proposed transaction was
unanimously approved by both the Sanofi and Ablynx Board of
Directors. The offer is comprised of two separate but concurrent
tender offers: (i) a tender offer under the laws of Belgium
for all of the outstanding shares, warrants and convertible bonds
of Ablynx (the "Belgian Offer") and
(ii) a tender offer under the laws of the U.S. for all of the
outstanding shares held by U.S. holders and ADSs held by holders,
wherever located (the "U.S. Offer" and
together with the Belgian Offer, the "Offers"). The initial acceptance period of the tender
offers commenced on 4 April 2018 and expired at 5:00 p.m. ET /
11:00 p.m. CET on 4 May 2018.
Sanofi confirmed on 14 May 2018
that, as of the expiration of the initial acceptance period, a
total of 71,972,994 shares (including 7,446,312 shares represented
by ADSs), 2,594,841 warrants and 975 convertible bonds had been
validly tendered into the Offers and not withdrawn. Sanofi owns
95.60% of the outstanding shares of Ablynx as of the settlement
date of the Offers, of which more than 90% were acquired through
the Offers. Sanofi further confirmed that the Minimum Tender
Condition and the other conditions to the Offers have been
satisfied.
Sanofi has decided to proceed with
a squeeze-out of those Securities not tendered to the Offers in
accordance with applicable Belgian and U.S. law. In this regard,
Sanofi reopened the Offers and commenced the squeeze-out period on
May 22, 2018, to acquire those Securities not previously tendered
into the Offers. The squeeze-out period will expire on June 12,
2018 at 5.00 p.m. New York City time / 11.00 p.m. CEST time.
Please see below for more
information on the tender offers.
For more information, please
contact
Ablynx
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Lies Vanneste
Director Investor Relations
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e: lies.vanneste@ablynx.com
Ablynx media
relations:
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Sukaina Virji
t: +44 (0)20 3709 5700
e: ablynx@consilium-comms.com
Joele Frank, Wilkinson Brimmer
Katcher
Dan Katcher or Joseph Sala
t: +1 212 355-4449
Additional information on the Belgian
Offer
An electronic version of the prospectus (including
the forms) can be found on the websites of the Receiving &
Paying Agents (for BNP Paribas Fortis NV/SA, https://www.bnpparibasfortis.be/epargneretplacer
(French and English) and https://www.bnpparibasfortis.be/sparenenbeleggen
(Dutch and English); for KBC Securities NV/SA in
cooperation with KBC Bank NV/SA, https://www.kbcsecurities.com/prospectus-documents-overviews/prospectus-overview,
https://www.kbc.be,
https://www.cbc.be and
https://www.bolero.be),
Sanofi (https://www.sanofi.com/en/investors/tender-offers-ablynx
and https://www.sanofi.com/fr/investisseurs/offres-ablynx)
and Ablynx (http://www.ablynx.com/investors/sanofi-takeover-bid/).
The Prospectus can also be obtained in hard copy free of charge
(i) at the counters of the Receiving & Paying Agents or
(ii) by contacting the Receiving & Paying Agents at
+32 (0)2 433 41 13 (BNP Paribas
Fortis NV/SA), +32 (0)78 15 21 53 (KBC Bank NV/SA, Dutch &
English), +32 (0) 800 92 020 (CBC Banque NV/SA, French
& English) or +32 32 83 29 81 (Bolero by KBC
Securities NV/SA, Dutch, French & English). The Prospectus
is available in English and Dutch. The summary of the prospectus is
also available in French.
The Response
Memorandum is annexed to the prospectus. The Response Memorandum
can also be obtained in hard copy free of charge at the registered
office of Ablynx (Technologiepark 21, 9052 Zwijnaarde (Belgium)).
The Response Memorandum is available in English and Dutch.
Additional Information on the U.S. Offer
This communication is for informational purposes
only and is neither a recommendation, an offer to purchase nor a
solicitation of an offer to sell any Securities of Ablynx. Sanofi
has filed a Tender Offer Statement on Schedule TO with the SEC and
Ablynx has filed a Solicitation/Recommendation Statement on
Schedule 14D-9 with the SEC. Holders of Securities are urged to
carefully review the documents that were filed by Sanofi and Ablynx
with the SEC because these documents will contain important
information, including the terms and conditions of the tender
offer.
The offer to
purchase, the related ADS letter of transmittal and certain other
tender offer documents, as well as the Solicitation/Recommendation
Statement are available to all holders of Securities of Ablynx at
no expense to them. These documents are available for free at the
SEC's website at www.sec.gov. Additional copies may be obtained for
free by contacting Sanofi at ir@Sanofi.com or
on Sanofi's website at https://en.Sanofi.com/investors. You should read the filings made by Sanofi and Ablynx
with the SEC carefully before making a decision concerning the U.S.
Offer.
pdf version of the press
release
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Ablynx via Globenewswire
Grafico Azioni Ablynx NV (NASDAQ:ABLX)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Ablynx NV (NASDAQ:ABLX)
Storico
Da Set 2023 a Set 2024